Literature DB >> 16702952

A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH.

R Roylance1, P Gorman, T Papior, Y-L Wan, M Ives, J E Watson, C Collins, N Wortham, C Langford, H Fiegler, N Carter, C Gillett, P Sasieni, S Pinder, A Hanby, I Tomlinson.   

Abstract

We analysed chromosome 16q in 106 breast cancers using tiling-path array-comparative genomic hybridization (aCGH). About 80% of ductal cancers (IDCs) and all lobular cancers (ILCs) lost at least part of 16q. Grade I (GI) IDCs and ILCs often lost the whole chromosome arm. Grade II (GII) and grade III (GIII) IDCs showed less frequent whole-arm loss, but often had complex changes, typically small regions of gain together with larger regions of loss. The boundaries of gains/losses tended to cluster, common sites being 54.5-55.5 Mb and 57.4-58.8 Mb. Overall, the peak frequency of loss (83% cancers) occurred at 61.9-62.9 Mb. We also found several 'minimal' regions of loss/gain. However, no mutations in candidate genes (TRADD, CDH5, CDH8 and CDH11) were detected. Cluster analysis based on copy number changes identified a large group of cancers that had lost most of 16q, and two smaller groups (one with few changes, one with a tendency to show copy number gain). Although all morphological types occurred in each cluster group, IDCs (especially GII/GIII) were relatively overrepresented in the smaller groups. Cluster groups were not independently associated with survival. Use of tiling-path aCGH prompted re-evaluation of the hypothetical pathways of breast carcinogenesis. ILCs have the simplest changes on 16q and probably diverge from the IDC lineage close to the stage of 16q loss. Higher-grade IDCs probably develop from low-grade lesions in most cases, but there remains evidence that some GII/GIII IDCs arise without a GI precursor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16702952      PMCID: PMC2687551          DOI: 10.1038/sj.onc.1209659

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  34 in total

1.  DNA microarrays for comparative genomic hybridization based on DOP-PCR amplification of BAC and PAC clones.

Authors:  Heike Fiegler; Philippa Carr; Eleanor J Douglas; Deborah C Burford; Sarah Hunt; Carol E Scott; James Smith; David Vetrie; Patricia Gorman; Ian P M Tomlinson; Nigel P Carter
Journal:  Genes Chromosomes Cancer       Date:  2003-04       Impact factor: 5.006

2.  Whose hypothesis? Ciphering, sectorials, D lesions, freckles and the operation of Stigler's Law.

Authors:  Scott E Kern
Journal:  Cancer Biol Ther       Date:  2002 Sep-Oct       Impact factor: 4.742

3.  Array comparative genomic hybridization analysis of colorectal cancer cell lines and primary carcinomas.

Authors:  Eleanor J Douglas; Heike Fiegler; Andrew Rowan; Sarah Halford; David C Bicknell; Walter Bodmer; Ian P M Tomlinson; Nigel P Carter
Journal:  Cancer Res       Date:  2004-07-15       Impact factor: 12.701

4.  Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma.

Authors:  E Shelley Hwang; Sarah J Nyante; Yunn Yi Chen; Dan Moore; Sandy DeVries; James E Korkola; Laura J Esserman; Frederic M Waldman
Journal:  Cancer       Date:  2004-06-15       Impact factor: 6.860

5.  Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23-qter and identifies underlying candidate tumor suppressor genes in prostate cancer.

Authors:  J E Vivienne Watson; Norman A Doggett; Donna G Albertson; Armann Andaya; Arul Chinnaiyan; Herman van Dekken; David Ginzinger; Christopher Haqq; Karen James; Sherwin Kamkar; David Kowbel; Daniel Pinkel; Lars Schmitt; Jeffry P Simko; Stanislav Volik; Vivian K Weinberg; Pamela L Paris; Colin Collins
Journal:  Oncogene       Date:  2004-04-22       Impact factor: 9.867

6.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.

Authors:  C W Elston; I O Ellis
Journal:  Histopathology       Date:  1991-11       Impact factor: 5.087

7.  Different mechanisms of chromosome 16 loss of heterozygosity in well- versus poorly differentiated ductal breast cancer.

Authors:  Anne-Marie Cleton-Jansen; Horst Buerger; Natalja ter Haar; Katja Philippo; Marc J van de Vijver; Werner Boecker; Vincent T H B M Smit; Cees J Cornelisse
Journal:  Genes Chromosomes Cancer       Date:  2004-10       Impact factor: 5.006

Review 8.  The interaction of oestrogen receptor status and pathological features with adjuvant treatment in relation to survival in patients with operable breast cancer: a retrospective study of 2660 patients.

Authors:  D M Barnes; R R Millis; C E Gillett; K Ryder; D Skilton; I S Fentiman; R D Rubens
Journal:  Endocr Relat Cancer       Date:  2004-03       Impact factor: 5.678

9.  Deciphering a subgroup of breast carcinomas with putative progression of grade during carcinogenesis revealed by comparative genomic hybridisation (CGH) and immunohistochemistry.

Authors:  E Korsching; J Packeisen; M W Helms; C Kersting; R Voss; P J van Diest; B Brandt; E van der Wall; W Boecker; H Bürger
Journal:  Br J Cancer       Date:  2004-04-05       Impact factor: 7.640

Review 10.  Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way.

Authors:  Manuela Santarosa; Alan Ashworth
Journal:  Biochim Biophys Acta       Date:  2004-06-07
View more
  20 in total

1.  Merotelic attachments and non-homologous end joining are the basis of chromosomal instability.

Authors:  Astrid Alonso Guerrero; Carlos Martínez-A; Karel Hm van Wely
Journal:  Cell Div       Date:  2010-05-17       Impact factor: 5.130

2.  Identification of metastasis-associated breast cancer genes using a high-resolution whole genome profiling approach.

Authors:  Mohamed M Desouki; Shaoxi Liao; Huayi Huang; Jeffrey Conroy; Norma J Nowak; Lori Shepherd; Daniel P Gaile; Joseph Geradts
Journal:  J Cancer Res Clin Oncol       Date:  2010-08-03       Impact factor: 4.553

Review 3.  The genomic landscape of retinoblastoma: a review.

Authors:  Brigitte L Thériault; Helen Dimaras; Brenda L Gallie; Timothy W Corson
Journal:  Clin Exp Ophthalmol       Date:  2013-05-22       Impact factor: 4.207

4.  Genomic heterogeneity of breast tumor pathogenesis.

Authors:  Rachel E Ellsworth; Jeffrey A Hooke; Craig D Shriver; Darrell L Ellsworth
Journal:  Clin Med Oncol       Date:  2009-07-29

5.  Zinc Finger Homeodomain Factor Zfhx3 Is Essential for Mammary Lactogenic Differentiation by Maintaining Prolactin Signaling Activity.

Authors:  Dan Zhao; Gui Ma; Xiaolin Zhang; Yuan He; Mei Li; Xueying Han; Liya Fu; Xue-Yuan Dong; Tamas Nagy; Qiang Zhao; Li Fu; Jin-Tang Dong
Journal:  J Biol Chem       Date:  2016-04-20       Impact factor: 5.157

6.  Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer.

Authors:  L W M Loo; C Ton; Y-W Wang; D I Grove; H Bouzek; N Vartanian; M-G Lin; X Yuan; T L Lawton; J R Daling; K E Malone; C I Li; L Hsu; P L Porter
Journal:  Genes Chromosomes Cancer       Date:  2008-12       Impact factor: 5.006

7.  Immunophenotypic and genomic characterization of papillary carcinomas of the breast.

Authors:  Raphaëlle Duprez; Paul M Wilkerson; Magali Lacroix-Triki; Maryou B Lambros; Alan MacKay; Roger A'Hern; Arnaud Gauthier; Vidya Pawar; Pierre-Emanuel Colombo; Frances Daley; Rachael Natrajan; Eric Ward; Gaëtan MacGrogan; Flavie Arbion; Patrick Michenet; Britta Weigelt; Anne Vincent-Salomon; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2011-12-09       Impact factor: 7.996

8.  The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through Wnt/β-catenin signaling and silenced in common carcinomas.

Authors:  L Li; J Ying; H Li; Y Zhang; X Shu; Y Fan; J Tan; Y Cao; S W Tsao; G Srivastava; A T C Chan; Q Tao
Journal:  Oncogene       Date:  2011-12-05       Impact factor: 9.867

9.  Atbf1 regulates pubertal mammary gland development likely by inhibiting the pro-proliferative function of estrogen-ER signaling.

Authors:  Mei Li; Xiaoying Fu; Gui Ma; Xiaodong Sun; Xueyuan Dong; Tamas Nagy; Changsheng Xing; Jie Li; Jin-Tang Dong
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

10.  An array CGH based genomic instability index (G2I) is predictive of clinical outcome in breast cancer and reveals a subset of tumors without lymph node involvement but with poor prognosis.

Authors:  Françoise Bonnet; Mickael Guedj; Natalie Jones; Sana Sfar; Véronique Brouste; Nabila Elarouci; Guillaume Banneau; Béatrice Orsetti; Charlotte Primois; Christine Tunon de Lara; Marc Debled; Isabelle de Mascarel; Charles Theillet; Nicolas Sévenet; Aurélien de Reynies; Gaëtan MacGrogan; Michel Longy
Journal:  BMC Med Genomics       Date:  2012-11-27       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.